- €49.21bn
- €48.90bn
- €7.74bn
Brief: UCB's Rystiggo Gets EU Approval For Two New Administration Methods
Barclays cautious on European pharma in H1, sees re-rating chance in H2
Brief: UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)
Brief: UCB, XtalPi Unit Partner Up On Biologics AI Platform
UCB slides after experimental Parkinson's drug misses targets in trial
Refile: French and Benelux stocks-Factors to watch
Brief: UCB: ORCHESTRA Minzasolmin Study Doesn't Meet Primary Or Secondary Clinical Endpoints
Brief: UCB Receives U.S. FDA Approval For Bimzelx® (Bimekizumab-Bkzx)
Brief: UCB Receives U.S. FDA Approval For Bimzelx
Brief: UCB Presents Dapirolizumab Pegol Phase 3 Data
European pharma stocks slip after Trump taps RFK Jr to lead top US health agency
Brief: UCB Raises 2024 Guidance, Completes Sale Of Established Brands
Brief: UCB Presents Data On Bepranemab In Early Alzheimer's Disease In Phase 2A Study
Europe Research Roundup: Clariant, M6, Ucb
Brief: UCB Receives U.S. FDA Approval For 320 Mg Single-Injection Device Presentations Of Bimzelx (Bimekizumab-Bkzx)
Brief: EMA Has Started Review Of Medicines Containing Finasteride & Dutasteride Following Concerns Regarding Suicidal Ideation
Brief: UCB Announces A Study Evaluating Bimzelx Versus Skyrizi In Psoriatic Arthritis
Brief: UCB Announces Late-Breaking 2 Year Data For Bimekizumab In HS
Brief: UCB Introduces New 4-Year Data For Bimzelx